The progression of Alzheimer disease might be monitored by measuring the rate of hippocampal volume loss by means of MRI. Research suggests that a reduction in hippocampal volume can be detected over a period as short as 6 months, and that such volume loss is associated with cognitive decline and other indicators of Alzheimer disease neuropathology.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Differential expression of pyroptosis-related genes in the hippocampus of patients with Alzheimer’s disease
BMC Medical Genomics Open Access 14 March 2023
-
Early diagnosis of Alzheimer’s disease using machine learning: a multi-diagnostic, generalizable approach
Alzheimer's Research & Therapy Open Access 03 August 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Henneman, W. J. et al. Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures. Neurology 72, 999–1007 (2009).
Schuff, N. et al. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 132, 1067–1077 (2009).
Barnes, J. et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol. Aging doi:10.1016/j.neurobiolaging.2008.01.010.
Raber, J., Huang, Y. & Ashford, J. W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25, 641–650 (2004).
van de Pol, L. A. et al. Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology 69, 1491–1497 (2007).
van der Vlies, A. E. et al. Most rapid cognitive decline in APOEε4 negative Alzheimer's disease with early onset. Psychol. Med. doi:10.1017/S0033291709005492
Hansson, O. et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228–234 (2006).
Verwey, N. A. et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann. Clin. Biochem. 46, 235–240 (2009).
Olsson, A. et al. Simultaneous measurement of β-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 51, 336–345 (2005).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
van der Flier, W., Scheltens, P. Hippocampal volume loss and Alzheimer disease progression. Nat Rev Neurol 5, 361–362 (2009). https://doi.org/10.1038/nrneurol.2009.94
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2009.94
This article is cited by
-
Differential expression of pyroptosis-related genes in the hippocampus of patients with Alzheimer’s disease
BMC Medical Genomics (2023)
-
Hippocampus: Molecular, Cellular, and Circuit Features in Anxiety
Neuroscience Bulletin (2023)
-
Early diagnosis of Alzheimer’s disease using machine learning: a multi-diagnostic, generalizable approach
Alzheimer's Research & Therapy (2022)
-
Common hippocampal structural and functional changes in migraine
Brain Structure and Function (2013)
-
Changing perspectives regarding late-life dementia
Nature Reviews Neurology (2009)